Genetics Institute Inc. has been enjoined from manufacturingerythropoietin (EPO) in the United States. Monday's ruling, byJudge William Young of the U.S. District Court forMassachusetts, had been expected. It doesn't affect Cambridge,Mass.-based GI's operations, since GI ceased manufacturingEPO in the United States following a March 5 ruling by theCourt of Appeals for the Federal Circuit.

The appeals panel held that GI's patent claims for EPO wereinvalid. GI on July 1 petitioned the Supreme Court to overturnthat decision.

GI stock (NASDAQ:GENI) closed unchanged on Monday at $29.50.

(c) 1997 American Health Consultants. All rights reserved.